- Home
- HOWL vs RNXT Comparison
HOWL vs RNXT Comparison
Compare HOWL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- RNXT
- Stock Information
- Founded
- HOWL 2017
- RNXT 2012
- Country
- HOWL United States
- RNXT United States
- Employees
- HOWL N/A
- RNXT N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- RNXT Health Care
- Exchange
- HOWL Nasdaq
- RNXT Nasdaq
- Market Cap
- HOWL 47.1M
- RNXT 44.6M
- IPO Year
- HOWL 2021
- RNXT 2021
- Fundamental
- Price
- HOWL $1.36
- RNXT $1.27
- Analyst Decision
- HOWL Strong Buy
- RNXT Strong Buy
- Analyst Count
- HOWL 3
- RNXT 2
- Target Price
- HOWL $8.33
- RNXT $7.25
- AVG Volume (30 Days)
- HOWL 554.2K
- RNXT 118.6K
- Earning Date
- HOWL 08-07-2025
- RNXT 08-14-2025
- Dividend Yield
- HOWL N/A
- RNXT N/A
- EPS Growth
- HOWL N/A
- RNXT N/A
- EPS
- HOWL N/A
- RNXT N/A
- Revenue
- HOWL $1,143,000.00
- RNXT $240,000.00
- Revenue This Year
- HOWL N/A
- RNXT $3,104.65
- Revenue Next Year
- HOWL N/A
- RNXT $301.89
- P/E Ratio
- HOWL N/A
- RNXT N/A
- Revenue Growth
- HOWL N/A
- RNXT N/A
- 52 Week Low
- HOWL $0.60
- RNXT $0.75
- 52 Week High
- HOWL $4.18
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- HOWL 60.96
- RNXT 45.64
- Support Level
- HOWL $1.25
- RNXT $1.23
- Resistance Level
- HOWL $1.44
- RNXT $1.35
- Average True Range (ATR)
- HOWL 0.10
- RNXT 0.06
- MACD
- HOWL 0.02
- RNXT -0.01
- Stochastic Oscillator
- HOWL 68.89
- RNXT 23.53
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.